Abstract
Summary At present, the problem of drug resistant malaria is basically that of treatment and control in South America and southeast Asia of strains of P. falciparum resistant to chloroquine. Some of these strains are resistant to quinine and many of them to the folic reductase inhibitors pyrimethamine and chlorguanide (proguanil). Treatment, both prophylactic and curative, involves to an increasing extent the use of sulfones and sulfonamides, occasional failure of which may be attributable to host factors rather than extension of parasite resistance to these drugs. Pending the arrival of effective new antimalarial compounds still in various stages of testing, several prophylactic and curative regimens are available for use in the field or clinic, and these are described. Fundamental to control are the observations, by no means conclusive, that the strains are no more virulent in man than are chloroquine sensitive ones, and that they are not preferentially carried by certain anophelines inaccessible or resistant to insecticidal attack.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The American journal of tropical medicine and hygiene
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
